Physician profile
Jennifer Morrow
NPI 1477656536
$2,274.96
in general payments reported to CMS, 2019-2025
23 companies · $315 in 2025
The $315 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $114 · 2021: $185 · 2022: $429 · 2023: $266 · 2024: $271 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $473.11 | 2019-2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $365.14 | 2022-2025 | |
| Abbott Laboratories | $189.88 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.53 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $146.50 | 2019 | |
| Pfizer INC. | $133.31 | 2019-2025 | |
| Boston Scientific Corporation | $109.30 | 2023-2024 | |
| Heartflow, INC. | $106.66 | 2025 | |
| Abiomed | $95.13 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $88.23 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $87.83 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $66.37 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $57.26 | 2024-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $39.23 | 2022 | |
| Arbor Pharmaceuticals, INC. | $27.99 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $16.88 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $16.53 | 2023 | Inpefa |
| Esperion Therapeutics, INC. | $15.78 | 2024 | Nexletol |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.92 | 2021 | |
| Astellas Pharma US INC | $13.73 | 2019 | |
| Merck Sharp & Dohme LLC | $13.61 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.04 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.